Equities analysts expect that Biopharmx Corp (NYSE:BPMX) will report sales of $20,000.00 for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Biopharmx Corp’s earnings, with the highest sales estimate coming in at $30,000.00 and the lowest estimate coming in at $10,000.00. Biopharmx Corp posted sales of $30,000.00 during the same quarter last year, which suggests a negative year over year growth rate of 33.3%. The business is scheduled to announce its next quarterly earnings report on Tuesday, December 12th.

On average, analysts expect that Biopharmx Corp will report full year sales of $20,000.00 for the current fiscal year, with estimates ranging from $50,000.00 to $570,000.00. For the next financial year, analysts expect that the firm will post sales of $5.08 million per share, with estimates ranging from $50,000.00 to $15.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that follow Biopharmx Corp.

Shares of Biopharmx Corp (NYSE BPMX) opened at $0.18 on Friday.

WARNING: This piece was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/11/04/20000-00-in-sales-expected-for-biopharmx-corp-bpmx-this-quarter.html.

Biopharmx Corp Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Get a free copy of the Zacks research report on Biopharmx Corp (BPMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.